The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues and long-lived tangible assets by geographic area.

The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Three Months Ended September 30,
	2019		2018
Americas	$	29,429	$	32,694
Europe, Middle East, India and Africa		31,600		36,035
Asia Pacific		14,067		12,177
Japan		14,481		14,923
Total	$	89,577	$	95,829

Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands):

	September 30,		June 30,
	2019		2019
Americas	$	13,660	$	13,853
Europe, Middle East, India and Africa	$	493		575
Asia Pacific		1,322		1,419
Japan		1,207		1,275
Total	$	16,682	$	17,122